RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called
durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer.
Durvalumab is a drug that has been developed to activate the immune system by blocking a
protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal
cells, including immune cells.